AT-752

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Good, Steven S: 2 articles (01/2022 - 10/2021)
2.	Julander, Justin G: 2 articles (01/2022 - 10/2021)
3.	Lin, Kai: 2 articles (01/2022 - 10/2021)
4.	Moussa, Adel: 2 articles (01/2022 - 10/2021)
5.	Sommadossi, Jean-Pierre: 2 articles (01/2022 - 10/2021)
6.	Weight, Abbie E: 1 article (01/2022)
7.	Canard, Bruno: 1 article (10/2021)
8.	Collu, Gabriella: 1 article (10/2021)
9.	La Colla, Paolo: 1 article (10/2021)
10.	Shannon, Ashleigh: 1 article (10/2021)

1.	Infections 10/18/2021 - "The demonstrated in vitro and in vivo activity of AT-752 suggests that it is a promising compound for the treatment of dengue virus infection and is currently under evaluation in clinical studies." 01/01/2022 - "The demonstrated in vivo activity of AT-752 suggests that it is a promising compound for clinical development in the treatment of YFV infection." 01/01/2022 - "Treatment with 1000 mg/kg AT-752 for 7 days, initiated 4 h prior to viral challenge, reduced viremia to below the limit of detection by day 4 post infection (pi) and returned ALT to normal levels by day 6 pi. "
2.	Viremia 10/18/2021 - "In AG129 mice infected with DENV D2Y98P, treatment with AT-752 significantly reduced viremia and morbidity and increased survival. " 01/01/2022 - "Treatment with 1000 mg/kg AT-752 for 7 days, initiated 4 h prior to viral challenge, reduced viremia to below the limit of detection by day 4 post infection (pi) and returned ALT to normal levels by day 6 pi. "
3.	Dengue (Dengue Fever) 10/18/2021 - "Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses."